Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report

Jian Gong; Weiwei Wu; Liguo Qiu; Xi Wang; Jianwei Bao; Jinjing Wang; Lifang Cheng; Zhiyuan Fu; Fengming Hu

doi:10.2147/CCID.S395348

Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report

Clin Cosmet Investig Dermatol. 2022 Dec 30:15:2949-2956. doi: 10.2147/CCID.S395348. eCollection 2022.

Authors

Jian Gong^#^{1

2}, Weiwei Wu^#³, Liguo Qiu^{1

2}, Xi Wang^{1

2}, Jianwei Bao^{1

2}, Jinjing Wang⁴, Lifang Cheng^{1

2}, Zhiyuan Fu^{1

5}, Fengming Hu^{1

2}

Affiliations

¹ Department of Integrated Traditional Chinese and Western Medicine of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People's Republic of China.
² Jiangxi Provincial Clinical Research Center for Skin Diseases, Nanchang, Jiangxi, People's Republic of China.
³ Department of Plastic and Dermatological Surgery, The Fifth People's Hospital of Hainan Province, Haikou, Hainan, People's Republic of China.
⁴ Clinical School of Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
⁵ Department of Pharmacy, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People's Republic of China.

^# Contributed equally.

Abstract

Psoriasis is an immune-mediated chronic inflammatory dermatosis influenced by hereditary and environmental factors. Human immunodeficiency virus (HIV) infection affects the immune system and exacerbates psoriatic lesions. We report the case of a 33-year-old male patient diagnosed with psoriasis vulgaris, psoriatic arthritis and HIV infection. Acitretin capsules, etanercept and high-active antiretroviral therapy (HAART) were effective. Two months after etanercept was discontinued, his condition worsened. After switching to secukinumab combined with HAART, the symptoms of psoriatic arthritis resolved rapidly after four weeks, with a Disease Activity Index for Psoriatic Arthritis score of 0. The time to achieve psoriasis area and severity index 40, 75, 90, and 100 were 2, 4, 8, and 29 weeks. The treatment was maintained for 1 year with no adverse reactions. Regarding the stable CD4⁺ T lymphocyte count and the viral load, administering anti-IL-17 monoclonal antibodies is an effective treatment option for psoriasis patients.

Keywords: HIV; biologics; etanercept; psoriasis; secukinumab.

Publication types

Case Reports

Grants and funding

This work was supported by the Construction Project of Hainan Province Clinical Medical Center, general projects of science and technology plan of Jiangxi Province Administration of Traditional Chinese Medicine (NO.2021B108) and Jiangxi Provincial Clinical Research Center for Skin Diseases (NO.20212BCG 74003).